Inactive Instrument

HBL - Hadasit Bio-Holdings Ltd Share Price TEL AVIV STOCK EXCHANGE

Equities

HDST

IL0010954050

Biotechnology & Medical Research

Financials

Sales 2022 - Sales 2023 - Capitalization 7.43M 1.95M 163M
Net income 2022 -31M -8.14M -679M Net income 2023 -29M -7.62M -635M EV / Sales 2022 -
Net cash position 2022 12.93M 3.4M 283M Net cash position 2023 6.46M 1.7M 141M EV / Sales 2023 -
P/E ratio 2022
-0.46 x
P/E ratio 2023
-0.25 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 25%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 20/15/20
Chairman 60 18/14/18
Comptroller/Controller/Auditor 53 31/15/31
Members of the board TitleAgeSince
Director/Board Member 68 29/18/29
Director/Board Member 66 05/16/05
Director/Board Member 53 01/17/01
More insiders
HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Company’s subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company’s framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
More about the company